Colorectal cancer is the third most common cancer worldwide and the fourth most common cause of cancer death. The median survival for patients with metastatic colorectal cancer (mCRC) has been 16-20 months when using fluoropyrimidine and either oxaliplatin or Irinotecan. The addition of bevacizumab to classical chemotherapeutic regimens in the treatment of metastatic colorectal cancer has been shown to increase median survival by around 5 months however data specifically in patients from the Middle East is lacking. This is a regional, multicenter, prospective, non-interventional observational study to assess the efficacy and safety of treatment with Bevacizumab and chemotherapy in mCRC patients in routine clinical care in Lebanon.